

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vriginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
: 09/529,342	07/27/2000	DAVID J. CLARKE	39-206	8022
75	90 09/24/2003			
NIXON & VANDERHYE			EXAMINER	
1100 NORTH C 8TH FLOOR	GLEBE ROAD		YANG, NELSON C	
	VA 22201-4714			
	711 22201 1711		ART UNIT	PAPER NUMBER
			1641	
			DATE MAILED: 09/24/2003	1
				111
				( )

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>y</b>	Application No.	Applicant(s)				
Office Action Summany	09/529,342	CLARKE ET AL.				
Office Action Summary	Examin r	Art Unit				
T. MAIL DIO DATE AU.	Nelson Yang	1641				
The MAILING DATE of this communication app ars on the cover sh et with the correspondenc address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status	36(a). In no event, howe y within the statutory mini vill apply and will expire S , cause the application to	ver, may a reply be timely filed mum of thirty (30) days will be considered timely. SIX (6) MONTHS from the mailing date of this communication. become ABANDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on <u>09 J</u>	<u>lune 2003</u> .					
2a)☐ This action is <b>FINAL</b> . 2b)☑ Th	is action is non-fir	nal.				
3) Since this application is in condition for allowards closed in accordance with the practice under Disposition of Claims						
4)⊠ Claim(s) <u>1-41</u> is/are pending in the application	<b>).</b>					
4a) Of the above claim(s) is/are withdraw	wn from considera	ation.				
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-41 are subject to restriction and/or	election requireme	ent.				
Application Papers						
9) The specification is objected to by the Examine						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the						
11) The proposed drawing correction filed on						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Ex	aminer.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign	priority under 35	U.S.C. § 119(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the prior application from the International But</li> <li>* See the attached detailed Office action for a list</li> </ul>	reau (PCT Rule 1	7.2(a)).				
14) Acknowledgment is made of a claim for domestic	c priority under 35	U.S.C. § 119(e) (to a provisional application	1).			
<ul> <li>a)  The translation of the foreign language pro</li> <li>15) Acknowledgment is made of a claim for domesting</li> </ul>	• •					
Attachment(s)		•				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲	Interview Summary (PTO-413) Paper No(s)  Notice of Informal Patent Application (PTO-152)  Other:				



Application/Control Number: 09/529,342

Art Unit: 1641

## DETAILED ACTION

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-17, drawn to a method comprised of the special technical feature of monitoring for a species incorporated into lipid vesicle particles targeted to a cell type to be detected.

Group II, claim(s) 2-9, 18-22, drawn to a method comprised of the special technical feature of modulating the activity of a cell type of interest using a species incorporated into lipid vesicle particles targeted to a cell type to be detected.

Group III, claim(s) 23-41, drawn to a lipid vesicle particle used for treatment of medical conditions.

2. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The application contains claims to more than one of the combinations of categories of inventions as set forth by 37 CFR 1.475.

## According to 37 CFR 1.475 regarding unity of invention:

(a) An international and a national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept ("requirement of unity of invention"). Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

Application/Control Number: 09/529,342

Art Unit: 1641

. 🗳

ľ

(b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:

- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and a process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.

If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) above, unity of invention might not be present. Furthermore, the determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

3. Unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more special technical features. The term "special technical features" is defined as meaning those technical features that define a contribution which each of the inventions considered as a whole, makes over the prior art. The determination is made based on the contents of the claims as interpreted in light of the description and drawings.

Group I involves the special technical feature of detecting a cell type of interest by monitoring directly or indirectly a species incorporated into lipid vesicle particles.

Group II has the special technical feature of modulating the activity of a cell type of interest with a species incorporated into lipid vesicles.

Group III has the special technical feature lipid vesicle particles that contain cytolytic peptides and particles.

4. Furthermore, Woodle et al [5,843,473] teaches that liposomes have been proposed as a drug carrier for intravenously (IV) administered compounds, including both imaging and therapeutic compounds (column 3, lines 5-8).

Page 3

Application/Control Number: 09/529,342

Art Unit: 1641

5. A telephone call was made to Mary J. Wilson on September 22, 2003 to request an oral

election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37 CFR

1.143).

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a request under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Nelson Yang whose telephone number is 703-305-4508. The

examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Long V Le can be reached on 703-305-3399. The fax phone number for the

organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-0196.

NY

LONG V. LE SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600 Page 4

eg had